Related Experiment Video
Updated: Jun 4, 2025
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
SARS-CoV-2 Vaccination in Primary Humoral Immunodeficiency: Experience from a German Lung Clinic
Sophie Rosendahl1, Franziska C Trudzinski1, Markus Polke1
1Department of Pneumology and Critical Care Medicine, Thoraxklinik University of Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany.
Introduction:
During the COVID-19 pandemic, the effectiveness of vaccines against SARS-CoV-2 in immunodeficient patients not only did affect the individual risk of these vulnerable patients but endangered the selection of new variants of concern due to prolonged virus shedding by these patients.
Methods:
In a tertiary center for pulmonary diseases, we investigated the immune response of 11 patients with primary humoral immunodeficiency and 13 healthy controls on the humoral and cellular level after full vaccination with an mRNA or vector vaccine against SARS-CoV-2.
Results:
In the majority of patients (73%), we found antibodies against the spike protein above the threshold of positivity. Likewise, patients showed a promising cellular response: the upregulated production of INFγ, TNFα, and CXCL10 by T cells did not differ from the response of healthy controls.
Conclusion:
These results stress the importance to further discern an adequate immunological correlate of protection and the need to follow the effect of booster immunizations in this population at risk.
More Related Videos
Related Concept Videos
01:25Immunodeficiency Diseases
There are three main causes of immunodeficiency...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:51Vaccinations